Eligible patients will receive full MS patient support program through Cycle Vita™
Boston, Massachusetts and San Jose, California – November 1, 2022 – Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
The launch of TASCENSO ODT aims to address the withdrawal of the Gilenya® (fingolimod) capsules patient support program (Go Program®) on March 31, 20231. Eligible patients* prescribed TASCENSO ODT will have access to patient support from Cycle Vita™, Cycle’s dedicated, in-house patient support hub, designed specifically with the needs of patients in mind.
The launch follows a partnership between Cycle and Handa Neuroscience, LLC (Handa), the developer of TASCENSO ODT, to commercialize both the 0.25mg and 0.5mg strengths in the US. The patient support provided through Cycle Vita will ensure that eligible patients are able to continue on, or initiate, fingolimod treatment with TASCENSO ODT while receiving access to patient support such as appropriate insurance navigation, financial assistance, first-dose observation and baseline assessments beyond March 31, 2023. [read more]